Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Challenges in treating cancers of unknown primary (CUP)

Thomas Helleday • 29 Sep 2019
ESMO 2019
General

Thomas Helleday, MD, PhD, Karolinska Institute, Stockholm, Sweden & University of Sheffield, Sheffield, UK, highlights the issues with treating cancers of unknown primary (CUP), which result in a poor prognosis for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Thomas Helleday

2:40
Targeting the DNA damage response
Thomas Helleday • 29 Sep 2019
1:25
PARP inhibitors for ovarian cancer - room for improvement with HRD testing
Thomas Helleday • 30 Sep 2019
2:49
Immunotherapy priming with neo-antigens
Thomas Helleday • 1 Jun 2019
3:07
The DNA damaging revolution
Thomas Helleday • 1 Jun 2019

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals